erlotinib hydrochloride has been researched along with deoxyglucose in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (deoxyglucose) | Trials (deoxyglucose) | Recent Studies (post-2010) (deoxyglucose) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 11,426 | 171 | 1,375 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knudson, CM; Kowalski, CE; Love-Homan, L; Orcutt, KP; Parsons, AD; Simons, AL; Sobhakumari, A | 1 |
1 other study(ies) available for erlotinib hydrochloride and deoxyglucose
| Article | Year |
|---|---|
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Chloroquine; Deoxyglucose; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Female; Glucose; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2016 |